费城染色体样急性淋巴细胞白血病的研究进展

Research progress of Philadelphia chromosome-like acute lymphoblastic leukemia

费城染色体样急性淋巴细胞白血病(Philadelphia chromosome-like acute lymphoblastic leukemia,Ph-like ALL),又称Ph样急性淋巴细胞白血病或BCR-ABL1样急性淋巴细胞白血病,其基因表达谱与费城染色体阳性急性淋巴细胞白血病(Ph+ALL)相似,但缺乏BCR-ABL1融合基因易位[1-2]。

Philadelphia chromosome-like acute lymphoblastic leukemia(Ph-like ALL) also be known as BCR/ABL1-like acute lymphoblastic leukaemia. Gene expression profiling is heterogeneous in Ph-like ALL. Ph-like ALL is generally considered to be associated with a series of molecular abnormalities associated with the activation of cytokine receptors and kinase signaling pathways, and is often associated with the development of lymphoid transcription factor gene abnormalities. Early diagnosis is critical because targeted drug therapy can significantly improve the prognosis of patients with ph-like ALL. This paper intends to review the clinical features, gene profiles, diagnostic patterns and current treatment strategies of Ph-like ALL for the purpose of early identification of patients and corresponding targeted therapy or clinical trials.